ALG 1001

Drug Profile

ALG 1001

Alternative Names: ALG-1001; Integrin Peptide Therapy; Luminate

Latest Information Update: 16 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Allegro Ophthalmics
  • Class Eye disorder therapies; Oligopeptides
  • Mechanism of Action Integrin alpha 5 beta 1 modulators; Integrin alpha2beta1 modulators; Integrin alphaVbeta3 modulators; Integrin alphaVbeta5 modulators; Protein tyrosine kinase inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Diabetic retinopathy; Retinal disorders; Wet age-related macular degeneration

Most Recent Events

  • 09 Aug 2017 Efficacy and adverse events data from the phase IIb DEL MAR trial in Diabetic macular oedema released by Allegro Opthalmics
  • 25 Jul 2017 Allegro Ophthalmics plans multiple phase III trials in USA
  • 15 Dec 2016 Phase-II clinical trials in Diabetic macular oedema (Adjunctive treatment) in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top